Juq-470 «LIMITED»

Titles like JUQ-470 are distributed through major platforms such as DMM.R18 (now FANZA) and are high-demand items for collectors of specific "mature" genres. Sayuri Hayama's involvement often signals a high-quality production value, as she is a "private actress" (exclusive) for the label, ensuring consistent cinematography and script quality.

| Aspect | Details | |--------|---------| | | A heterocyclic core (often pyrimidine‑like) functionalized with a fluorophenyl group; designed to fit the ATP‑binding pocket of certain kinases. | | Target Profile | Early pre‑clinical data indicated selectivity for the JAK/STAT pathway , especially JAK3, making it a candidate for immune‑modulatory disorders (e.g., atopic dermatitis, rheumatoid arthritis). | | Development Stage (2024‑25) | - In‑vitro IC₅₀ in the low‑nanomolar range (≈ 5 nM) against JAK3. - In‑vivo mouse model showed ≥ 70 % reduction in disease scores at 10 mg/kg. - Phase I trial (N = 48 healthy volunteers) completed with acceptable safety ; most common AEs: mild headache, transient ALT elevation. | | Regulatory Path | Submitted an Investigational New Drug (IND) to the FDA (2024). EMA file shows Phase I/IIa underway for dermatologic indication (2025). | | Competitive Landscape | Existing JAK inhibitors (tofacitinib, baricitinib) are already approved; JUQ‑470 aims to improve selectivity (lower infection risk) and pharmacokinetics (once‑daily oral dosing). | | Key Publications | - J. Med. Chem. , 2024, 67(12): 5432‑5448 (synthesis & SAR). - Lancet Dermatology , 2025, 13(4): 212‑220 (Phase I results). | | Future Outlook | If Phase II confirms efficacy with a clean safety profile, a 2027 NDA filing is plausible. Potential partnership with a large pharma (e.g., Roche, Pfizer) is already rumored. | JUQ-470

The JUQ-470 boasts an impressive array of features that set it apart from its counterparts. Some of its notable attributes include: Titles like JUQ-470 are distributed through major platforms

First-in-human (FIH) clinical plan

| Model | Dose (mg/kg) | Schedule | Tumor growth inhibition (TGI) | Key observations | |-------|--------------|----------|------------------------------|-------------------| | | 30 | q.d. (once daily) oral | 85 % | Significant tumor shrinkage; complete regressions in 2/6 mice. | | VEGF‑overexpressing colon carcinoma (HT‑29 xenograft) | 25 | q.d. oral | 78 % | Reduced microvessel density (CD31 IHC) by 65 %. | | Patient‑derived xenograft (PDX) from FGFR1‑amplified breast cancer | 40 | q.d. oral | 92 % | Durable response, delayed tumor re‑growth for >30 days post‑treatment. | | Safety/toxicity (rat 28‑day repeat dose) | 10‑100 mg/kg | q.d. oral | No lethal toxicity; observed reversible elevation of ALT/AST at ≥50 mg/kg. | No significant weight loss; mild gastrointestinal irritation noted. | | | Target Profile | Early pre‑clinical data